Clinipace CEO, founder resigns as CEO

Clinipace CEO, founder resigns as CEO

Transition in Power

Clinipace CEO, founder resigns as CEO

After 14 years, Jeff Williams, co-founder and chief executive officer of Morristown, New Jersey-based Clinipace Worldwide, is moving into an expanded advisory role with the company’s board of directors and turning over the CEO job to Jason Monteleone. The new CEO most recently founded Pivotal Financial Consulting, LLC, a strategic financial consulting firm serving the clinical research industry with a special focus on CROs.

Over the past three years, Williams has been an acquisitive CEO, having led the acquisition of six companies.  Clinipace, a worldwide full-service clinical research organization (CRO), helps to advance drug candidates for venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, according to an article by Ben Adams in Fierce Biotech.  “The company leverages extensive therapeutic knowledge and clinical trial expertise to support life science firms in achieving their most important goals: executing regulatory strategies, optimizing clinical development timelines and completing high-quality trials,” Adams said.

Clinipace, which has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects, operates in North America, South America, Europe, and Asia Pacific. The company, which has more than 800 employees in 39 countries,  serves midsized biotech and medical device companies with its end-to-end eClinical platform, which  Damian Garde of Fierce Biotech describes as ”an efficient, cost-effective method for managing data and running trials in a wealth of therapeutic areas.”

In April 2015, Clinipace bought German-based Accovion, which has run clinical trials around Europe for more than 10 years, maintaining eight international subsidiaries and doing business in 20 countries. Prior to that, Clinipace bought out Hong Kong CRO Choice Pharma in 2014, shortly after buying Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.

Williams, who  will continue with Clinipace as a director focusing on strategic initiatives, started the company in 2003 “with the desire to leverage technology in new ways to improve the way clinical research is conducted,” according to a company statement.  Today, the company is considered to be one of the top 15 CROs in the industry. 

According to Williams, “I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO.  After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.” 

Monteleone, who has more than 20 years of experience in clinical research, life science and healthcare-related organizations, said, “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”

Monteleone has served as executive vice president and chief financial officer of Theorem Clinical Research, chief financial officer of Omnicare Clinical Research, senior finance director of MDS Pharma Services and finance director at VIASYS Healthcare. He holds an MBA in finance from Temple University and a BS in Business Administration from Millersville University of Pennsylvania.

Amazon and Everybody Else

Amazon and Everybody Else

Next Big Thing?: Blockchain may have a place in healthcare

Next Big Thing?: Blockchain may have a place in healthcare